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ABSTRACT
The cleavage reaction of topoisomerase II, which
creates double-stranded DNA breaks, plays a central
role in both the cure and initiation of cancer.
Therefore, it is important to understand the cellular
processes that repair topoisomerase II-generated
DNA damage. Using a genome-wide approach with
Saccharomyces cerevisiae, we found that Dmre11,
Dxrs2, Drad50, Drad51, Drad52, Drad54, Drad55,
Drad57 and Dmms22 strains were hypersensitive to
etoposide, a drug that specifically increases levels
oftopoisomeraseII-mediatedDNA breaks.These res-
ults confirm that the single-strand invasion path-
way of homologous recombination is the major
pathway that repairs topoisomerase II-induced DNA
damage in yeast and also indicate an important role
for Mms22p. Although Dmms22 strains are sensitive
toseveralDNA-damagingagents,littleisknownabout
the function of Mms22p. Dmms22 cultures accumu-
late in G2/M, and display an abnormal cell cycle
responsetotopoisomeraseII-mediatedDNAdamage.
MMS22 appears to function outside of the single-
strand invasion pathway, but levels of etoposide-
induced homologous recombination in Dmms22
cells are lower than wild-type. MMS22 is epistatic
with RTT101 and RTT107, genes that encode its pro-
teinbindingpartners.Finally,consistentwitharolein
DNAprocesses,Mms22plocalizestodiscretenuclear
foci, even in the absence of etoposide or its binding
partners.
INTRODUCTION
In order for an organism to survive, it must be able to with-
stand an array of challenges that damage its genetic material.
It has long been known that environmental events can trigger
the loss of bases, the formation of DNA adducts or the
generation of DNA strand breaks (1–4). More recently, it
has become clear that many normal cellular processes also
have the capacity to destabilize the genome (5). For example,
lipid peroxidation products and radicals generated by oxidat-
ive phosphorylation damage bases and induce DNA strand
breaks. In addition, enzymes involved in DNA replication
and recombination can incorporate incorrect bases, or create
chromosomal translocations, insertions or deletions.
Of the enzymes involved in ongoing DNA processes, topo-
isomerase II potentially is the most lethal (6–13). This essential
enzyme is required to remove knots and tangles from the gen-
ome (10,14,15). It acts by passing an intact DNA double helix
through a transient double-stranded break that it generates in a
separate segment of DNA (6–8,11,16). In order to maintain the
integrity of the genome during the DNA strand passage event,
topoisomeraseIIforms covalentbonds between activesitetyro-
syl residues and the newly created 50-termini of the cleaved
DNA (17–19). These covalent protein–DNA complexes are
referred to as cleavage complexes. If a cleavage complex is
encountered by a DNA tracking system such as a polymerase or
a helicase, the ensuing collision converts this transient protein–
DNAcomplex(byaprocessthatisnotyetfullyunderstood)toa
permanent DNA strand break (20–24). Since topoisomerase II
cleavage complexes normally are ﬂeeting catalytic intermedi-
ates and are present in low concentrations, they are tolerated by
the cell. However, conditions that increase either the concen-
tration or lifetime of these complexes convert topoisomerase II
into a potent cellular toxin that fragments the genome (8,25).
The potentially lethal nature of topoisomerase II has been
exploited to treat a number of human cancers. Drugs such as
etoposide target the enzyme and kill cells by dramatically
increasingphysiological levelsofcleavagecomplexes(26,27).
Because of their mechanism of action, these anticancer agents
are known as topoisomerase II poisons to distinguish them
from drugs that act by inhibiting the overall catalytic activity
of the enzyme (6).
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doi:10.1093/nar/gki246Despite the importance of topoisomerase II in cancer
chemotherapy, there is mounting evidence that the enzyme
triggers chromosomal breaks that result in speciﬁc leukemias.
A small proportion of patients who receive topoisomerase
II-targeted drugs as part of their treatment subsequently
develop secondary leukemias with characteristic breakpoints
in the MLL gene at chromosomal band 11q23 (13,28–30).
Infant and adult leukemias that display 11q23 rearrangements
also have been correlated to exposure to naturally occurring
or environmental topoisomerase II poisons (13,29,31–33).
Because the type II enzyme plays an important role in both
the cure and the generation of cancer, it is important to under-
stand the processes by which cells protect themselves from
topoisomerase II-mediated DNA damage. A previous study
utilized Saccharomyces cerevisiae as a model system to
identify the recombination pathways that repair DNA strand
breaks that are generated by topoisomerase II (34). Etoposide-
induced cytotoxicity and DNA recombination were monitored
in a series of mutant strains that were singly deleted for genes
in known recombination repair pathways. Results of this
work suggested that the single-strand invasion pathway of
homologous recombination plays a major role in repairing
topoisomerase II-mediated DNA breaks (34).
Because the previous study investigated only known
recombination pathways, it is possible that other mechanisms
also help to protect cells from the damaging actions of
topoisomerase II. Therefore, the repair of topoisomerase
II-mediated DNA damage in yeast was reinvestigated using
a genome-wide approach. A S.cerevisiae haploid deletion
library containing  4800 isogenic strains (35) was screened
for hypersensitivity to etoposide.
Results conﬁrm the importance of the single-strand invasion
pathway of homologous recombination. In addition, MMS22
was found to play a signiﬁcant role in protecting yeast from
topoisomerase II-mediated DNA damage. Dmms22 strains
were  10-fold hypersensitive to topoisomerase II poisons.
Further studies indicate that Mms22p acts outside of the
single-strand invasion pathway, and is a nuclear protein that
localizes at discrete foci.
MATERIALS AND METHODS
Materials
Etoposide and amsacrine were obtained from Sigma, prepared
as 20 mM solutions in 100% DMSO, and stored at room
temperature. Growth media were prepared using standard
protocols.
Yeast strains and plasmids
Other than the initial screen for etoposide sensitivity (see
following section), all cellular studies employed S.cerevisiae
strains that carried the JN362acc background (MATa ura3-52
leu2 trp1 his7 ade1-2 ISE2 can1 cyh2) (26,36) (Table 1). For
homologous recombination assays, a JN362acc strain contain-
ing the top2S740W allele in place of the TOP2 gene was used
(34). Deletion mutants were generated using one-step gene
replacement (37) and were conﬁrmed by PCR of genomic
DNA. Genomic DNA was prepared using a MasterPure Yeast
DNA Puriﬁcation Kit (Epicentre). MMS22 was cloned using
PCR primers  250 bp upstream and downstream of the coding
region.TheclonewastheninsertedviaSacI/KpnIsites intothe
multiple cloning site of vector pRS416 to create the vector
pMMS22. The recombination reporter plasmid YCpHR has
been described previously (34,38).
Etoposide-sensitivity screen
A MATa (BY4741) haploid S.cerevisiae deletion library gen-
erated by the Saccharomyces Gene Deletion Project (35) was
screened forsensitivitytoetoposide. Strains inthelibrarywere
thawed and plated onto YPD medium containing drug solvent
(DMSO) or 1 mM etoposide. Plates were incubated at 30 C
and drug sensitivity was determined by cell density. Strains
that displayed high sensitivity to etoposide were conﬁrmed
by spotting serial dilutions to medium containing DMSO or
1 mM etoposide.
Drug cytotoxicity assays
JN362acc yeast strains ( 1–2 · 10
6 cells/ml) were incubated
in YPD or selective medium (to maintain plasmids) with
0–200 mM etoposide or 0–150 mM amsacrine for 8 or
24 h. Cells were plated in triplicate to corresponding medium
solidiﬁed with 1.5% Bacto-agar and incubated at 30 C for
3–4 days to visualize colonies. Drug sensitivity was monitored
by counting surviving colonies. For plate assays, cells were
spotted in 10-fold serial dilutions to media containing DMSO
or the indicated topoisomerase II poison.
FACS analysis of yeast
Wild-type and Dmms22 strains were grown in the presence of
DMSOor50mMetoposidefor6h.Cellswere ﬁxedwith100%
ethanol, resuspended in 50 mM sodium citrate (pH 7.0) con-
taining 0.08 mg/ml RNase A and incubated for 1 h at 50 C.
Proteinase K (0.25 mg/ml) was added and the mixture was
incubated for 1 h at 50 C. Cells were stained with 1 mM Sytox
Green (Molecular Probes) in 1 ml of 50 mM sodium citrate
(pH 7.0) for 1 h in the dark at room temperature. DNA content
was measured on a Becton Dickinson FACScan.
Determination of homologous recombination frequency
Homologous recombination frequency was determined as
previously described (34). Brieﬂy, strains transformed with
Table 1. Saccharomyces cerevisiae strains
Strain
a Genotype Strain origin
JN362acc MATa ura3-52 leu2 trp1 his7
ade1-2 ISE2 can1 cyh2
keda, derived from
Nitiss et al. (26,36)
MS001 top2S740W Sabourin et al. (34)
MS111c rad52::TRP Sabourin et al. (34)
EB001 mms22::KAN This study
EB002 rad54::TRP This study
EB003 mms22::KAN rad54::TRP This study
EB004 top2S740W mms22::KAN This study
EB005 rtt101::KAN This study
EB006 rtt107::KAN This study
EB007 mms22::HYG rtt101::KAN This study
EB008 mms22::TRP rtt107::KAN This study
EB009 rtt101::KAN rtt107::HYG This study
EB010 mms22::TRP rtt101::KAN
rtt107::HYG
This study
aAll strains are isogenic to JN362acc except where noted.
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overnight and diluted to 2 · 10
6 cells/ml. Cultures were
grown for 5 h in the presence of DMSO or 50–200 mM eto-
poside, and dilutions were plated in triplicate on SC-URA/
ARG medium to assess total cell viability or on SC-URA/
ARG + 60 mg/ml canavanine for selection of the recombined
plasmid. Recombined plasmids were analyzed by growing
single colonies from SC-URA/ARG + canavanine plates to
conﬂuency. To conﬁrm that canavanine resistance resulted
from a homologous recombination event, plasmids were
rescued into Escherichia coli using the EZ Yeast Plasmid
Prep Kit (Geno Technology, Inc.). The resulting E.coli trans-
formants were isolated, plasmid DNA was puriﬁed and
plasmids were digested with PstI.
GFP-Mms22p localization
An N-terminal GFP-Mms22p fusion was constructed by
cloning PCR-ampliﬁed MMS22 into the pGFP-N-FUS vector
at SmaI/XhoI sites (39). The resulting fusion protein was
expressed under the control of the MET25 promoter, therefore
cells were grown in SC-URA/MET medium to maintain the
plasmid and to induce the promoter. Dmms22, Dmms22
Drtt101, Dmms22 Drtt107 and Dmms22 Drtt101 Drtt107
strains were transformed with pGFP-N-FUS or pGFP-
MMS22. Cells were grown overnight and examined for ﬂuor-
escence through a GFP optimized ﬁlter (Chroma Technology)
on an Olympus BX60 microscope equipped with a Photomet-
rics Quantix digital camera. DNA was visualized using
Hoechst stain.
RESULTS
Double-stranded breaks in the genetic material are repaired
primarily by DNA recombination pathways. The most
common pathways used by the budding yeast, S.cerevisiae,
are depicted in Figure 1 (40–42). The initial processing of
double-stranded DNA breaks generally relies on the Rad50p/
Mre11p/Xrs2p complexto generate single-stranded ends atthe
site of the break (40–43). Following this processing, the DNA
can be shuttled into three well-characterized recombination
pathways (40–42). The break can be repaired by the single-
strand invasion pathway of homologous recombination. This
pathway, which utilizes Rad51p/52p/54p/55p/57p as well as
the replication machinery, is capable of repairing the initial
double-stranded DNA break in an error-free manner. Altern-
atively, the break can be repaired by the single-strand anneal-
ing pathway of homologous recombination. This pathway is
dependent on the presence of direct repeats (or closely related
sequences) proximal to and ﬂanking the initial break site.
It relies on Rad52p and the Rad1p/Rad10p endonuclease.
Single-strand annealing is not an error-free pathway and
deletes one of the repeated sequences, as well as the genetic
information that is located between them. Finally, the break
can be rejoined by the nonhomologous end-joining pathway
(40,41,44,45). This pathway utilizes Ku70p/Ku80p and Lig4p,
and results in the loss of sequences proximal to the original
DNA break. If multiple breaks are present in the genome,
nonhomologous end-joining can lead to the formation of
chromosomal rearrangements or translocations. In general,
homologous recombination pathways are considerably more
active than nonhomologous end-joining in S.cerevisiae.
Rad50 
Mre11 
Xrs2
Rad52
Ku70/80 
Lig4
Rad51 
Rad52 
Rad54 
Rad55 
Rad57
Nonhomologous Nonhomologous
End-Joining End-Joining
Homologous  Homologous 
Recombination Pathways Recombination Pathways
Replication 
Machinery
Rad1/10
Single-strand Invasion     Single-strand Invasion     Single-strand Annealing   Single-strand Annealing 
Figure 1. Pathways used to repair double-stranded DNA breaks in S.cerevisiae. Components of the pathways that play integral roles in homologousrecombination
and nonhomologous end-joining are shown. A previous study that used deletion mutants in these pathways suggested that the single-strand invasion pathway of
homologous recombination is primarily responsible for repairing topoisomerase II-generated DNA breaks that are stabilized by etoposide (34).
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A previous study analyzed cytotoxicity and recombination in a
series of strains that carried single deletions of genes involved
in each of the above pathways (34). Based on results with the
topoisomerase II poison, etoposide, this work concluded that
topoisomerase II-generated double-stranded DNA breaks are
repaired primarily by the single-strand invasion pathway of
homologous recombination. The non-homologous end-joining
pathway also is triggered by topoisomerase II-mediated DNA
cleavage, but due to its reduced presence in yeast, does not
contribute signiﬁcantly to cell survival (34).
Since that study examined only known repair pathways, it is
possible that other unidentiﬁed mechanisms help to protect
cells from the damaging actions of topoisomerase II. There-
fore, a genome-wide approach was used to further investigate
the repair oftopoisomerase II-mediated DNA damagein yeast.
To this end, a S.cerevisiae haploid deletion library of  4800
strains (35) was screened for sensitivity to topoisomerase
II-generated DNA breaks. These breaks were induced by
exposing yeast cultures to the topoisomerase II poison eto-
poside (34). This drug is speciﬁc for the type II enzyme and
kills cells by dramatically increasing levels of topoisomerase
II-mediated DNA breaks (26,27).
Deletion strains were plated onto medium containing either
1 mM etoposide or drug solvent (DMSO). The high concen-
tration of etoposide was required because normal laboratory
yeaststrainsdisplaypoordruguptake.SincethelossofRAD52
dramatically increases cytotoxicity to topoisomerase II poi-
sons by 2–3 orders of magnitude (34,36), a Drad52 deletion
strain was used as a positive control for drug hypersensitivity.
Strains that displayed an etoposide sensitivity that appro-
ached that of Drad52 were streaked onto plates containing
1 mM etoposide to re-examine cell growth. Deletion strains
that conferred drug hypersensitivity in this second screen were
spotted in serial dilutions onto medium containing the topo-
isomerase II poison (Figure 2). On the basis of these criteria,
nine strains that were at least 10-fold hypersensitive to eto-
poside were identiﬁed. The ﬁrst eight were Dmre11, Dxrs2,
Drad50, Drad51, Drad52, Drad54, Drad55 and Drad57.
Every one of these genes encodes a protein required for the
single-strand invasion pathway of homologous recombination
(40–42). In contrast, no strains with deletions in any gene
speciﬁc for the single-strand annealing or nonhomologous
end-joiningpathways(otherthanRAD52whichalsoisrequired
for single-strand invasion) were identiﬁed. These ﬁndings
conﬁrm the results of Sabourin et al. (34), and establish the
single-strand invasion pathway of homologous recombination
as the major pathway whereby S.cerevisiae cells repair topoi-
somerase II-generated DNA damage.
In addition to the above deletions, Dmms22 conferred
hypersensitivity to etoposide. Mms22p is a protein of
unknown function that is believed to be involved in DNA
repair (www.incyte.com) (46,47). Strains that are deleted
for MMS22 are hypersensitive to a variety of DNA damaging
agents, including methyl methanesulfonate, hydroxyurea,
bleomycin, ultraviolet- and ionizing-irradiation, and camp-
tothecin (46,48,49). The present study represents the ﬁrst
report that deletion of MMS22 also confers hypersensitivity
to topoisomerase II-mediated DNA strand breaks.
Hypersensitivity of Dmms22 to topoisomerase
II-mediated DNA breaks
As discussed above, most S.cerevisiae strains display low
permeability to topoisomerase II-targeted drugs. Therefore,
to further analyze the effects of Mms22p on the sensitivity
of cells to topoisomerase II-mediated DNA damage, the
MMS22 deletion was re-created in the JN362acc background.
This parental strain contains the ISE2 permeability mutation,
which allows facile drug uptake, and has been used for numer-
ous studies of agents that enhance topoisomerase II-mediated
DNA cleavage (34,36,50,51).
Cytotoxicity assays were carried out in the presence of two
topoisomerase II poisons, etoposide and amsacrine. As seen in
Figure 3, Dmms22 cells were  10-fold hypersensitive to both
topoisomerase II poisons. These results are as compared to
Drad52 cells, which were >100-fold hypersensitive.
To conﬁrm that the drug hypersensitivity of Dmms22 cells
resulted from the lack of Mms22p, the MMS22 gene under the
control of its endogenous promoter was cloned in a plasmid
vector (pMMS22). While a Dmms22 strain that carried the
empty vector was hypersensitive to etoposide, a Dmms22
strain that carried pMMS22 displayed wild-type sensitivity
(Figure 4). These data conﬁrm the initial deletion screen
and demonstrate that Mms22p protects cells from
DNA damage generated by topoisomerase II.
Effects of Mms22p on cell cycle distribution in the
presence of topoisomerase II-mediated DNA damage
A high proportion of Dmms22 populations exist as large-
budded cells in the absence of environmental insults (46).
Therefore, to further analyze the effects of Mms22p on cell
cycle distribution, FACS analysis was performed on asyn-
chronous wild-type and Dmms22 cells in the absence or
presence of etoposide. As shown in Figure 5, Dmms22 cells
displayed a phenotype distinct from that of wild-type cells.
Even in the absence of etoposide, the proportion of Dmms22
WT 
∆mre11
∆xrs2
∆rad50 
∆rad51
∆rad52
∆rad54
∆rad55
∆rad57
∆mms22
DMSO Etoposide
Figure 2. Genes involved in protecting cells from etoposide-induced DNA
damage. A S.cerevisiae haploid deletion library ( 4800 strains) was screened
for sensitivity to etoposide. Wild-type (WT, BY4741) and indicated deletion
strainswereplatedinserialdilutionontoYPDmediumcontainingdrugsolvent
(DMSO) or 1 mM etoposide.
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Figure 3. Dmms22 cells are hypersensitive to etoposide and amsacrine. The sensitivity of Dmms22 to topoisomerase II poisons was tested. Serial dilutions of
wild-type (WT), Dmms22 and Drad52 cultures were plated onto YPD medium containing DMSO or 100 mM drug (top). Cytotoxicity assays were performed using
the indicated strains. Cells were exposed to etoposide (bottom, left panel) or amsacrine (bottom, right panel) for 8 h in liquid culture. Error bars represent the SD
values of at least three independent experiments.
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Figure 4. Expression of plasmid-encoded MMS22 rescues the Dmms22 drug
hypersensitive phenotype. MMS22 was cloned, along with its endogenous
promoter, into pRS416 to generate pMMS22. Serial dilutions of the wild-
type strain carrying pRS416 (empty vector) as well as the Dmms22 strain
carrying either pRS416 or pMMS22 were plated onto SC-URA medium con-
tainingDMSOor100 mMetoposide(top). Cytotoxicity assayswereperformed
using the indicated strains (bottom). Cells were exposed to etoposide for 8 h in
liquid culture. Error bars represent the SD values of at least three independent
experiments.
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Figure 5. Dmms22 cells accumulate in G2/M. Asynchronous wild-type and
Dmms22cellsweregrownfor6hinthepresenceofDMSO(blackline)or50mM
etoposide (red line). Peaks representing haploid (1 N) and diploid (2 N) DNA
contents are indicated (top). The percent of cultures in G0/G1, S or G2/M phase
are shown (bottom). Cells were analyzed with Sytox Green as the DNA stain.
Results are representative of three independent experiments.
Nucleic Acids Research, 2005, Vol. 33, No. 3 1025cells in G0/G1 was only 60% of that observed for wild-type
cells. In addition, a signiﬁcantly higher proportion of the
mutant cells was in G2/M. The accumulation of cells in
G2/M suggests that Mms22p plays a role in allowing cells
to cope with endogenous damage in their genetic material.
The addition of 50 mM etoposide to cultures had little effect
on the cell cycle distribution of the parental strain. However,
there was a substantial decrease of cells in G0/G1 and an
increase in G2/M cells in the Dmms22 strain. These ﬁndings
provide additional evidence that Dmms22 cells display an
abnormal response to increased levels of topoisomerase
II-generated DNA breaks.
Mms22p does not appear to be part of the single-strand
invasion pathway of homologous recombination
TodeterminewhetherMms22pplaysaroleinthesingle-strand
invasion pathway or is part of a separate pathway that repairs
topoisomerase II-mediated DNA breaks, a Dmms22 Drad54
double mutant was constructed. Rad54p is a member of the
Swi2p/Snf2p superfamily of DNA-dependent ATPases and is
involved in joint-molecule formation during single-strand
invasion (40–42) (see Figure 1). Deletion of RAD54 sensitizes
yeast cultures to etoposide to a greater extent than observed
with a Dmms22 strain (Figure 6). As determined by serial dilu-
tion plate assays, the Dmms22 Drad54 double mutant was 1–2
orders of magnitude more sensitive to etoposide than either
single deletion mutant. Furthermore, the Dmms22 Drad54
double mutant was  3-fold more sensitive than the Drad54
strain in liquid culture cytotoxicity assays following a 24-h
drug exposure (Figure 6). These results indicate that MMS22
isnotepistatictoRAD54andsuggestthatMms22pactsoutside
of the single-strand invasion pathway of homologous recomb-
ination.AsimilarconclusionrecentlywasdrawnbyArakietal.
(47), based on the sensitivity of a Dmms22 Drad51 double
mutanttomethylmethanesulfonate.Takentogether,theseﬁnd-
ingsimplythatMms22prepresentspartofanovelpathwaythat
plays an important role in the cellular response to topoi-
somerase II-generated DNA damage.
Etoposide-induced homologous recombination is
lower in Dmms22 cells
Since the single-strand invasion pathway of homologous
recombination appears to be the major pathway by which
topoisomerase II-mediated DNA strand breaks are repaired,
the effects of deletion mutants on this process were character-
ized (Figure 7). A plasmid-based homologous recombination
reporter system was employed for these studies (34,38). In this
system, yeast strains are transformed with YCpHR, a plasmid
that contains the canavanine sensitivity gene, CAN1, ﬂanked
on either side by a copy of the LEU2 gene. Homologous
recombination between the two LEU2 genes results in the
deletion of CAN1. Since the chromosomal allele of CAN1 is
disrupted in the parental yeast strain, recombination is scored
by the ability of cells to grow in the presence of canavanine.
Yeast strains employed for these recombination studies all
harbored the mutant top2S740W yeast topoisomerase II allele
in place of the wild-type TOP2 gene. The S740W point muta-
tion, which has been well characterized, confers increased
etoposide sensitivity due to the formation of a more stable
drug-induced DNA cleavage complex (52). Inclusion of this
hypersensitive topoisomerase II allele promotes a greater cel-
lular response to etoposide and increases the levels of homo-
logous recombination observed with the reporter plasmid (34).
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II is hypersensitive to etoposide. Wild-type and Dmms22 cells containing the
top2S740W allele were exposed to etoposide for 5 h. Error bars represent
the SD values of four independent experiments.
1026 Nucleic Acids Research, 2005, Vol. 33, No. 3In the absence of etoposide, the frequency of homologous
recombination in Dmms22 cells was similar to that of the
parental MMS22 strain (Figure 7). However, signiﬁcant dif-
ferences were observed in the presence of the topoisomerase II
poison. Recombination frequencies in the MMS22 strain rose
 14-foldfollowingexposureto200mMetoposide.Incontrast,
frequencies in the Dmms22 strain rose only 4-fold over the
same drug range.
To verify that canavanine resistance arose from a homo-
logous recombination event on YCpHR rather than a micro-
deletion or point mutation in CAN1, plasmids were rescued
from Dmms22 colonies and analyzed by restriction enzyme
digestion (not shown). In all cases, the loss of canavanine
sensitivity was accompanied by a deletion of  6 kb. This
length corresponds to the size of the predicted CAN1 fragment
that would be lost following homologous recombination
between the two LEU2 genes.
Even though Mms22p does not appear to play a direct role
in the single-strand invasion pathway, these results strongly
suggest that the loss of this protein impairs the ability of yeast
cells to repair topoisomerase II-mediated DNA damage via
homologous recombination.
Drtt101 and Drtt107 strains are hypersensitive to
topoisomerase II-mediated DNA breaks
A high-throughput study that utilized mass spectrometry to
characterize protein complexes in S.cerevisiae identiﬁed
Rtt101p and Rtt107p as binding partners of Mms22p (53).
Both of these proteins appear to be involved in the regulation
of Ty1 transposition (54). In addition, Rtt101p displays
ubiquitin ligase activity (55), and Rtt107p has been identiﬁed
as a phosphorylation target of Mec1p and is believed to play
a role in the resumption of DNA synthesis following genomic
damage (56). To determine whether MMS22 is epistatic to
RTT101 or RTT107, a series of deletion mutants was construc-
ted in the JN362acc background and tested for sensitivity to
etoposide (Figure 8). The singly deleted Drtt101 and Drtt107
strains were  2-fold more sensitive to the topoisomerase II
poison than was the parental wild-type strain, while the
Drtt101 Drtt107 double mutant was  3-fold hypersensitive.
The sensitivity of the Dmms22 Drtt101 and Dmms22 Drtt107
double mutants, as well as the Dmms22 Drtt101 Drtt107 triple
mutant was similar to or less than that of Dmms22 alone. These
resultssuggestthatMMS22isepistatictoRTT101andRTT107,
and that the protein products of these three genes act within
the same pathway to repair topoisomerase II-generated DNA
damage.
Mms22p localizes to the nucleus at discrete foci
If Mms22p is involved in DNA repair processes, it would be
expected to localize in the nuclei of yeast cells. Therefore, to
analyze the cellular localization of Mms22p, a GFP-MMS22
hybrid gene construct was created using the pGFP-N-FUS
vector system. The construct was designed to generate an
N-terminal GFP-Mms22 fusion protein that was expressed
under the control of the MET25 promoter. As determined
by serial dilution plate assays, GFP-Mms22p is functional
(Figure 9). The etoposide sensitivity of Dmms22 cells that
harbored pGFP-MMS22 was comparable to that of wild-
type yeast (i.e. MMS22) that carried the pGFP-N-FUS.
In contrast, Dmms22 cells that harbored the pGFP-N-FUS
vector were hypersensitive to the drug.
Localization studies utilized Dmms22 cells that carried
either the pGFP-N-FUS vector or pGFP-MMS22 that
expressed the fusion construct. While GFP alone distributed
throughout the cell (with the exception of the vacuole), the
GFP-Mms22p fusion protein localized to the nucleus in
discrete foci (Figure 9). Similar results were observed in
the presence of etoposide (not shown).
Dmms22 Drtt101, Dmms22 Drtt107 and Dmms22 Drtt101
Drtt107 cells also were transformed with pGFP-N-FUS or
pGFP-MMS22. The localization of GFP and GFP-Mms22p
in these cells was similar to that described above (not
shown). These results imply that the localization of Mms22p
to nuclear foci does not require either of its binding partners,
Rtt101p or Rtt107p.
DISCUSSION
Although drugs that increase levels of topoisomerase
II-mediated DNA cleavage are front-line therapy for a variety
of human malignancies, considerable evidence suggests that
these same scission events can trigger the chromosomal breaks
that initiate speciﬁc leukemias (13,28–30). Despite the central
role that the type IIenzymeplays incuring and causing cancer,
the cellular pathways by which topoisomerase II-generated
DNA breaks are processed and repaired are not fully under-
stood. Therefore, budding yeast was used as a model genetic
system to address this important issue.
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Figure 8. MMS22 is epistatic to RTT101 and RTT107. Wild-type (WT);
Dmms22, Drtt101 and Drtt107 single mutant; Dmms22 Drtt101, Dmms22
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liquid culture. Error bars represent the SD values of at least three independent
experiments.
Nucleic Acids Research, 2005, Vol. 33, No. 3 1027A previous study that characterized individual deletion
mutants in known recombination pathways suggested that
the single-strand invasion pathway of homologous recombina-
tion plays an important role in the repair of topoisomerase
II-mediated DNA damage (34). To broaden the scope of
this earlier work, the present study utilized a genome-wide
approach in which a S.cerevisiae haploid deletion library was
tested for sensitivity to the topoisomerase II poison etoposide.
Eight of the nine strains that displayed >10-fold hyper-
sensitivity to the drug were deleted for components of
single-strand invasion. This ﬁnding conﬁrms the importance
of this yeast recombination pathway in the repair of topoi-
somerase II-generated DNA breaks.
The ninth strain that was identiﬁed in the screen was deleted
for MMS22. Dmms22 strains display increased sensitivity to
a variety of agents that induce DNA adducts or strand breaks,
or disrupt DNA replication (46,48,49). The present ﬁndings
extend the range of MMS22 to include the repair of DNA
damage generated by topoisomerase II.
It is notable that other strains were identiﬁed in the screen
that displayed mild hypersensitivity to etoposide (i.e.
<10-fold). Furthermore, since a haploid deletion library was
used for the present work, only non-essential genes could be
screened for sensitivity to the topoisomerase II poison. There-
fore, it is likely that further analysis of the yeast genome will
uncover additional genes that are involved in the cellular
response to topoisomerase II-mediated DNA damage.
A high-throughput proteomic study identiﬁed Rtt101p and
Rtt107p as binding partners of Mms22p (53). Drtt101 and
Drtt107 strains are hypersensitive to etoposide, albeit to a
lesser degree than Dmms22. Additional cytotoxicity studies
indicate that MMS22 is epistatic with RTT101 and RTT107.
These results are consistent with the known physical inter-
action between the three proteins and suggest that Mms22p,
Rtt101p and Rtt107p function in the same DNA repair
pathway.
Mms22p is localized to discrete foci within the nucleus,
even in the absence of etoposide. Punctate nuclear localization
patterns have been observed for other proteins that participate
in various damage response pathways, including DNA replica-
tion, cell cycle checkpoints and double-stranded DNA break
repair (57–63). Rad52p and other DNA repair proteins form
DNA repair centers following the induction of DNA damage
(57). However, foci are observed in a small percentage of cells
even in the absence of induced DNA breaks (58). Proteins
such as Sgs1p that are involved in the recovery of arrested
replication forks also are observed at discrete nuclear foci in
the absence of exogenous DNA damaging agents (60). Thus,
Mms22p may be involved in the repair of endogenous DNA
damage that accumulates during normal growth. Consistent
with this suggestion, Dmms22 strains display a high level of
G2/M cells in asynchronous populations.
Results of the present work and a previous genetic study
(47) indicate that MMS22 functions in a pathway that is
separate from the single-strand invasion pathway of homo-
logous recombination. If these pathways were completely
independent from one another, it might be expected that dele-
tion of MMS22 would shuttle topoisomerase II-induced DNA
damage into the single-strand invasion pathway, thereby
increasing levels of homologous recombination. However,
this was not the case. Following exposure to etoposide, the
increase in homologous recombination frequency in Dmms22
cells was several-fold lower than that observed in wild-type
cells. This ﬁnding implies that the MMS22 and single-strand
invasion pathways, although separate, must be linked.
Mms22p has no sequence homologs in mammalian cells
(www.incyte.com). At the present time, it is not known
whether this protein is unique to yeast or whether Mms22p
has functional homologs in higher organisms. With the excep-
tion of a nuclear localization signal, Mms22p contains no
known sequence motifs (www.incyte.com). Thus, it is difﬁcult
to speculate about the biochemical functions of this protein.
GFP DNA DIC
pGFP-N-FUS 
pGFP-MMS22
WT + pGFP-N-FUS 
∆mms22 + pGFP-N-FUS 
    ∆mms22 + pGFP-MMS22
DMSO Etoposide
Figure 9. GFP-Mms22p localizes to nuclear foci. Dmms22 cells containing a vector (pGFP-N-FUS) that expressed GFP or an N-terminal GFP-MMS22 fusion
construct (pGFP-MMS22) were examined for hypersensitivity to etoposide to confirm that the GFP-Mms22p fusion protein was functional. Wild-type (WT) cells
carryingpGFP-N-FUSaswellasDmms22cellscarryingeitherpGFP-N-FUSorpGFP-MMS22wereplatedinserialdilutionontoSC-MET/URAmediumcontaining
DMSO or 100 mM etoposide (top). GFP and the GFP-Mms22p fusion protein were visualized in cells by direct fluorescence microscopy. DNA was localized by
Hoechst staining. Differential image contrast (DIC) images of the visualized yeast cells are shown for reference.
1028 Nucleic Acids Research, 2005, Vol. 33, No. 3Since Dmms22 cells are sensitive to agents that induce a
variety of DNA aberrations (46,48,49), it is unlikely that
Mms22p is directly involved in processing topoisomerase II
from the termini of cleaved DNA. A previous study suggested
that Mms22p is involved in repairing aberrant DNA structures
that accumulate at replication forks in response to DNA dam-
age (47). In light of our genetic and recombination data, we
would further speculate that (i) the presence of these aberrant
DNA structures prevents the facile repair of the damage
by homologous recombination and other pathways; and (ii)
Mms22p, together with its partner proteins, helps to process
these aberrant DNA structures and convert them to a form that
can proceed into the different repair pathways.
The ﬁnding that Mms22p protects cells from topoisomerase
II-mediatedDNAdamageaddsanewlevelofcomplexitytoour
knowledge of the downstream pathways that process strand
breaksgeneratedbythe typeIIenzyme. Itisbecomingincreas-
ingly obvious that multiple pathways impact the response of
cells to topoisomerase II-DNA cleavage complexes. Some
repair the damage appropriately, some repair the damage
but generate inappropriate chromosomal rearrangements,
and some trigger cell death. Understanding the interplay
between these pathways provides critical information that
helps to dissect the opposing roles of topoisomerase II as a
target for cancer chemotherapy and as an agent that initiates
leukemic chromosomal translocations in humans.
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